Filing To Observe: Why Roberto Mignone’s Bridger Management Reported Big Trovagene, Inc Position?

Filing To Observe: Why Roberto Mignone's Bridger Management Reported Big Trovagene, Inc Position?

The New Roberto Mignone’s Bridger Management Holding in Trovagene, Inc

Bridger Management filed with the SEC SC 13G form for Trovagene, Inc. The form can be accessed here: 000089534516000596. As reported in Roberto Mignone’s Bridger Management’s form, the filler as of late owns 8% or 2,460,626 shares of the Health Care–company.

Trovagene, Inc stake is a new one for the for the hedge fund and it was filed because of activity on November 11, 2016. We feel this shows Roberto Mignone’s Bridger Management’s positive view for the stock. For a hedge fund managing $3.11 billion in assets and having 18+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Roberto Mignone’s Bridger Management’s US equities portfolio is in this sector.

Trovagene, Inc Institutional Sentiment

Latest Security and Exchange filings show 56 investors own Trovagene, Inc. The institutional ownership in Q3 2015 is high, at 31.14% of the outstanding shares. This is increased by 799737 the total institutional shares. 9534161 were the shares owned by these institutional investors. In total 10 funds opened new Trovagene, Inc stakes, 30 increased stakes. There were 20 that closed positions and 10 reduced them.

Windsor Financial Group Llc is an institutional investor bullish on Trovagene, Inc, owning 62500 shares as of Q3 2015 for 0.17% of its portfolio. Messner & Smith Theme Value Investment Management Ltd owns 38400 shares or 0.43% of its portfolio. NY Bridger Management Llc have 1.28% of their stock portfolio for 3290587 shares. Further, Elkhorn Partners Limited Partnership reported stake worth 0.15% of its US stock portfolio. The NY Morgens Waterfall Vintiadis & Co Inc owns 790000 shares. Trovagene, Inc is 2.48% of the manager’s US portfolio.

Business Profile

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q2. Its down 0.84, from 1.65 in 2016Q1. The ratio fall, as 8 funds sold all TrovaGene Inc shares owned while 23 reduced positions. 14 funds bought stakes while 11 increased positions. They now own 9.19 million shares or 9.18% less from 10.12 million shares in 2016Q1.

Tower Cap Ltd (Trc) holds 0% or 1,063 shares in its portfolio. Teachers Advsrs holds 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 48,120 shares. Spot Trading Ltd Company accumulated 0% or 6,865 shares. Royal State Bank Of Canada last reported 0% of its portfolio in the stock. Princeton has 0.22% invested in the company for 69,270 shares. California State Teachers Retirement accumulated 0% or 59,077 shares. Da Davidson Company holds 0.03% or 207,373 shares in its portfolio. D E Shaw Inc holds 15,104 shares or 0% of its portfolio. Manufacturers Life Ins Communications The holds 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 1,275 shares. Alliancebernstein Ltd Partnership holds 0% or 13,700 shares in its portfolio. The Delaware-based Blackrock Advisors Ltd Liability has invested 0% in TrovaGene Inc (NASDAQ:TROV). Goldman Sachs Grp Inc, a New York-based fund reported 193,454 shares. Citigroup accumulated 0% or 1,667 shares. Elkhorn Partners Partnership, a Nebraska-based fund reported 55,913 shares. Rhumbline Advisers has 0% invested in the company for 39,171 shares.

The stock decreased 1.67% or $0.05 during the last trading session, hitting $2.95. About 593,992 shares traded hands or 158.22% up from the average. TrovaGene Inc (NASDAQ:TROV) has declined 44.85% since April 13, 2016 and is downtrending. It has underperformed by 48.78% the S&P500.

Trovagene, Inc. is a molecular diagnostic company. The company has a market cap of $88.83 million. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. It currently has negative earnings. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

TrovaGene Inc (NASDAQ:TROV) Ratings Coverage

Out of 5 analysts covering TrovaGene (NASDAQ:TROV), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. $10 is the highest target while $5 is the lowest. The $6.33 average target is 114.58% above today’s ($2.95) stock price. TrovaGene has been the topic of 8 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Janney Capital on Friday, March 11. The rating was initiated by Cantor Fitzgerald with “Buy” on Tuesday, September 15. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, April 25. The rating was downgraded by Leerink Swann on Tuesday, April 26 to “Sector Perform”. The stock has “Outperform” rating given by Leerink Swann on Friday, August 14. The stock of TrovaGene Inc (NASDAQ:TROV) has “Neutral” rating given on Monday, April 25 by Piper Jaffray. The stock has “Market Perform” rating given by Avondale on Tuesday, March 29.

More notable recent TrovaGene Inc (NASDAQ:TROV) news were published by: Prnewswire.com which released: “Trovagene to Present at the BIO Investor Forum in San Francisco on October 19” on October 17, 2016, also Prnewswire.com with their article: “Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference” published on July 05, 2016, Prnewswire.com published: “Trovagene Announces HPV Patent Issuance by U.S. Patent and Trademark Office …” on November 07, 2016. More interesting news about TrovaGene Inc (NASDAQ:TROV) were released by: Zacks.com and their article: “Why Is Trovagene Inc. (TROV) Stock Soaring Today?” published on January 21, 2016 as well as Prnewswire.com‘s news article titled: “Trovagene Schedules Release of Second Quarter 2016 Financial Results and …” with publication date: July 26, 2016.

According to Zacks Investment Research, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.”

TROV Company Profile

Trovagene, Inc. (TrovaGene), incorporated on September 21, 2009, is a molecular diagnostic company. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Firm has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment